Kena C. Miller

1.8k total citations
69 papers, 1.4k citations indexed

About

Kena C. Miller is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Kena C. Miller has authored 69 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 31 papers in Oncology and 29 papers in Genetics. Recurrent topics in Kena C. Miller's work include Multiple Myeloma Research and Treatments (35 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Lymphoma Diagnosis and Treatment (17 papers). Kena C. Miller is often cited by papers focused on Multiple Myeloma Research and Treatments (35 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Lymphoma Diagnosis and Treatment (17 papers). Kena C. Miller collaborates with scholars based in United States, Germany and Canada. Kena C. Miller's co-authors include Asher Chanan‐Khan, Myron S. Czuczman, Zale P. Bernstein, Swaminathan P. Iyer, Paul K. Wallace, Alice Mohr, David Lawrence, Kenichi Takeshita, Joseph D Tariman and Francisco J. Hernandez‐Ilizaliturri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Kena C. Miller

69 papers receiving 1.3k citations

Peers

Countries citing papers authored by Kena C. Miller

Since Specialization

Citations

This map shows the geographic impact of Kena C. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kena C. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kena C. Miller more than expected).

Fields of papers citing papers by Kena C. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kena C. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kena C. Miller. The network helps show where Kena C. Miller may publish in the future.

Co-authorship network of co-authors of Kena C. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Kena C. Miller. A scholar is included among the top collaborators of Kena C. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kena C. Miller. Kena C. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recognizing the Contributions of Advanced Practitioners to Oncology Care: Are Current Metrics Enough? 2016 ·Journal of the Advanced Practitioner in Oncology ·(unknown), (unknown), Kena C. Miller	4
2	Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients 2012 ·PubMed ·Abhisek Swaika, Aneel Paulus, Kena C. Miller, Taimur Sher, Nikolaos G. Almyroudis, (unknown), (unknown), Aisha Masood, Kelvin Lee, Asher Chanan‐Khan	24
3	A steroid‐independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients 2011 ·British Journal of Haematology ·Taimur Sher, Sikander Ailawadhi, Kena C. Miller, (unknown), (unknown), Wei Phin Tan, Gregory E. Wilding, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri, (unknown), Raman Sood, (unknown), William T. Lawrence, (unknown), Aisha Masood, (unknown), Kelvin Lee, Asher Chanan‐Khan	10
4	Maintaining Bone Health in Patients With Multiple Myeloma 2011 ·Clinical journal of oncology nursing ·(unknown), Kathleen Colson, Beth Faiman, Kena C. Miller, Joseph D Tariman	28
5	Downregulation of BCL2 by AT‐101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner 2011 ·British Journal of Haematology ·Aisha Masood, Kasyapa S. Chitta, Aneel Paulus, A. Nazmul H. Khan, Taimur Sher, (unknown), Kena C. Miller, (unknown), Sikander Ailawadhi, (unknown), Kelvin P. Lee, Asher Chanan‐Khan	24
6	Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response 2010 ·Cancer ·Asher Chanan‐Khan, Kena C. Miller, David Lawrence, Swaminathan P. Iyer, Austin Miller, (unknown), Myron S. Czuczman, Paul K. Wallace, Jerome B. Zeldis, Kelvin H. Lee	66
7	Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide 2010 ·Clinical journal of oncology nursing ·Kena C. Miller, Laurie Musial, (unknown), Asher Chanan‐Khan	6
8	Plasma cell leukaemia and other aggressive plasma cell malignancies 2010 ·British Journal of Haematology ·Taimur Sher, Kena C. Miller, George Deeb, Kelvin Lee, Asher Chanan‐Khan	29
9	Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics 2010 ·Leukemia & lymphoma ·Taimur Sher, Kena C. Miller, David Lawrence, (unknown), Francisco J. Hernandez‐Ilizaliturri, Myron S. Czuczman, Austin Miller, William T. Lawrence, (unknown), Raman Sood, (unknown), AnneMarie W. Block, Kelvin Lee, Asher Chanan‐Khan	70
10	Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis 2010 ·Leukemia & lymphoma ·Rachid Baz, Mehul Patel, (unknown), Daniel Lebovic, Mohamad A. Hussein, Kena C. Miller, (unknown), Taimur Sher, Kelvin Lee, Asher Chanan‐Khan	13
11	Remission Induction With Lenalidomide Alone in a Patient With Previously Untreated Plasmablastic Myeloma: A Case Report 2009 ·Clinical Lymphoma & Myeloma ·Taimur Sher, Kena C. Miller, Kelvin Lee, Asher Chanan‐Khan	6
12	Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial 2009 ·Leukemia & lymphoma ·Asher Chanan‐Khan, Kena C. Miller, Laurie Musial, Swaminathan P. Iyer, Jihnhee Yu, Sikander Ailawadhi, Taimur Sher, Alice Mohr, Zale P. Bernstein, Maurice Barcos, Mehul Patel, D. Iancu, Kelvin Lee, Myron S. Czuczman	17
13	Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma 2009 ·Cancer ·Sikander Ailawadhi, (unknown), (unknown), Terry Mashtare, Kena C. Miller, Gregory E. Wilding, Ronald Alberico, Ronald H. Gottlieb, Donald Klippenstein, Kelvin Lee, Asher Chanan‐Khan	20
14	Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation's Nurse Leadership Board 2008 ·Clinical journal of oncology nursing ·(unknown), Elizabeth Bilotti, Kathleen Colson, Kathleen M. Curran, Deborah Doss, Beth Faiman, Maria Gavino, Bonnie Jenkins, K Lilleby, (unknown), Patricia Mangan, Emily McCullagh, (unknown), Kena C. Miller, (unknown), (unknown), (unknown), Lisa C. Smith, Joseph D Tariman, (unknown)	13
15	Bortezomib in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Multiple Myeloma 2007 ·Clinical Lymphoma & Myeloma ·Rami Manochakian, Kena C. Miller, Asher Chanan‐Khan	9
16	Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study 2006 ·Journal of Clinical Oncology ·Asher Chanan‐Khan, Kena C. Miller, Laurie Musial, David Lawrence, Swaminathan P. Iyer, Kenichi Takeshita, Carl W. Porter, David W. Goodrich, Zale P. Bernstein, Paul K. Wallace, David Spaner, Alice Mohr, Catriona Byrne, Francisco J. Hernandez‐Ilizaliturri, (unknown), Petr Starostik, Myron S. Czuczman	314
17	Supportive Care in Multiple Myeloma 2006 ·Clinical Lymphoma & Myeloma ·Asher Chanan‐Khan, Kena C. Miller	9
18	Clinical Characteristics of Gastrointestinal Lymphomas Associated with AIDS (GI-ARL) and the Impact of HAART 2004 ·HIV Clinical Trials ·Sridhar Srinivasan, Kenichi Takeshita, Beata Holkova, Myron S. Czuczman, Kena C. Miller, Zale P. Bernstein, Deborah Driscoll, Asher Chanan‐Khan	3
19	A multicenter Phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome‐associated Kaposi's sarcoma 2002 ·Cancer ·Zale P. Bernstein, Asher Chanan‐Khan, Kena C. Miller, Donald W. Northfelt, Gabriel Lopez‐Berestein, Parkash S. Gill	14
20	Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS 2002 ·HIV Clinical Trials ·Zale P. Bernstein, Stephen P. Brooks, Asher Chanan‐Khan, Sandra O. Gollnick, M. Jean Gilbert, Kena C. Miller, Thomas B. Tomasi	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact